Compare AstraZeneca plc (AZN) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Xcel Energy Inc — how do they compare? AstraZeneca plc trades at $159 (market cap $248.14B), while Xcel Energy Inc trades at $77.47 (market cap $48.51B). The key difference: AstraZeneca plc is far larger — about 5.1× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| AZN | XEL | |
|---|---|---|
Market Cap | $248.14B | $48.51B |
Sector | Health | Utilities |
52-Week High | $209.48 | $83.91 |
52-Week Low | $147.06 | $71.75 |
Enterprise Value | $275.41B | $86.82B |
Dividend Yield | 2.01% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Xcel Energy (XEL) trades at $78.33, up 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%. Analysts maintain a consensus buy rating with a $93.80 price target, highlighting growth from a $60 billion capital plan through 2030.
The outlook for XEL is positive due to projected EPS growth and rising electricity demand, but risks include regulatory pushback on rate increases and high capital expenditure. The stock offers stability with a dividend yield, yet valuation remains near historical highs, requiring careful monitoring of execution against its expansive investment strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
